Envoy Medical (COCH) Liabilities and Shareholders Equity (2020 - 2026)

Envoy Medical has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $29.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 187.16% year-over-year to $29.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.5 million (up 48.36% YoY) and the FY2025 annual result came in at $8.6 million, down 25.83% from the prior year.
• Liabilities and Shareholders Equity rose to $29.8 million in Q1 2026 per COCH's latest filing, from $8.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $427.8 million in Q3 2022 and troughed at $2.6 million in Q4 2022.
• A 5-year average of $90.4 million and a median of $10.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity tumbled 99.4% in 2022, then surged 223.59% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.6 million in 2022, then soared by 223.59% to $8.3 million in 2023, then surged by 39.5% to $11.5 million in 2024, then slipped by 25.83% to $8.6 million in 2025, then surged by 248.47% to $29.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $29.8 million, $8.6 million, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.